2-Year Follow-Up of Baroreflex Activation Therapy for Severe Heart Failure With Reduced Ejection Fraction

• DOI: 10.1016/j.jaccas.2024.103090
• Publication Date: 2025-03-05T19:13:01Z
• Authors: Sofia Jacinto; Ana Rita Teixeira; António Gonçalves; Rita Ilhão Moreira; Tiago Pereira da ...; Ana Teresa Timóteo; Rui Cruz Ferreira; Mário Martins Oli...
• Keywords: Fraction (chemistry)

Baroreflex activation therapy (BAT) is a novel treatment for heart failure with reduced ejection fraction (HFrEF) in patients who remain symptomatic despite optimal medical (OMT) and are unsuitable cardiac resynchronization (CRT). BAT modulates the autonomic nervous system by electrically stimulating carotid baroreceptors, thus potentially improving function symptoms. Two male HFrEF nonischemic cardiomyopathy, (NYHA functional class III) OMT, underwent successful implantation. Patient 1, 41-year-old man left ventricular (LVEF) of 34%, patient 2, 49-year-old an LVEF 21%, showed significant improvements at 2-year follow-up, including increased LVEF, N-terminal pro-B-type natriuretic peptide, better exercise capacity, relief II). Both avoided hospital readmissions had no complications. This case series demonstrates BAT's potential clinical outcomes ineligible CRT. Further research necessary to confirm these findings larger groups.